Viralym-C

About Cytomegalovirus (CMV)

  • In HSCT recipients, CMV can cause pneumonitis, gastroenteritis, fevers, hepatitis, encephalitis, retinitis, and can even lead to death
  • Currently available antivirals are not always effective and their prolonged use results in significant toxicity and risk of drug resistance

Viralym-C

Viralym-C (virus-specific lymphocytes against CMV) is a “ready to administer” T cell immunotherapy product made up of a generated bank of third-party, partially HLA-matched CMV-directed T cells that have been activated from exposure to CMV. We are currently conducting a Phase I clinical trial of Viralym-C at The Methodist Hospital and Texas Children’s Hospital in Houston, TX. For more information, please visit ClinicalTrials.gov: NCT02313857

ClinicalTrials.gov: NCT02313857